Effect of laparoscopic sleeve gastrectomy on vasoactive mediators in obese hypertensive patients: A prospective study

Introduction The causal relationship between obesity and high blood pressure is established; however, the detailed pathways for such association are still under research. This work aims to assess the changes in neprilysin, vasoconstrictor and vasodilatory molecules in obese hypertensive patients und...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 2021-02, Vol.94 (2), p.193-203
Main Authors: Salman, Ahmed Abdallah, Salman, Mohamed Abdalla, Shawkat, Mohamed, Hassan, Shady A., Saad, Eman H., Hussein, Ahmed Mahmoud, Refaie, Osama R. M., Tourky, Mohamed Sabry, Shaaban, Hossam El‐Din, Abd Allah, Nesrin, El Domiaty, Heba Fathy, Elkassar, Hesham
Format: Article
Language:English
Subjects:
Aldosterone
Angiotensin
Angiotensin II
Angiotensinogen
Atrial natriuretic peptide
Blood pressure
Endothelins
Gastrectomy
Hypertension
laparoscopic sleeve gastrectomy
Laparoscopy
Neprilysin
Obesity
Peptides
Remission
Renin
Surgery
Vasoactive agents
vasoactive mediators
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The causal relationship between obesity and high blood pressure is established; however, the detailed pathways for such association are still under research. This work aims to assess the changes in neprilysin, vasoconstrictor and vasodilatory molecules in obese hypertensive patients undergoing laparoscopic sleeve gastrectomy (LSG). Patients The present prospective study was done on 59 hypertensive obese patients in whom LGS was performed. Blood pressure, as well as blood samples for neprilysin, angiotensinogen, angiotensin II, renin, endothelin‐1 "ET‐1", aldosterone, atrial natriuretic peptide "ANP" and B‐type natriuretic peptide "BNP", were assessed before and 15 months after surgery. Patients were divided into two groups according to the remission of hypertension (HTN). Results After 15 months, remission of hypertension was seen in 42 patients (71%). The declines in the following measurements were significantly higher in patients with remission than those with persistent HTN: aldosterone (p = .029567), angiotensin II (p 
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.14352